Canada markets closed

Mindset Pharma Inc. (MSSTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2500-0.0273 (-9.84%)
At close: 03:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2773
Open0.2534
BidN/A x N/A
AskN/A x N/A
Day's Range0.2452 - 0.2573
52 Week Range0.2398 - 0.8416
Volume6,240
Avg. Volume23,151
Market Cap23.186M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin

    TORONTO, June 22, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Company has entered into an innovative research collaboration with the Centre for Addiction and Mental Health (“CAMH”), a top psychiatric research

  • GlobeNewswire

    Mindset Pharma Receives Notice of Allowance for Patent Application Covering Psilocin Derivatives for the Treatment of Central Nervous System Disorders

    TORONTO, June 10, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Mindset’s patent application number 17/387,845, titled, “

  • GlobeNewswire

    Mindset Pharma to Participate in Upcoming Conferences in June 2022

    TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that management will participate in three upcoming conferences: Grizzle Psychedelics Con 2022 to be held virtually on Wednesday, June 8, 2022. James Lanthi